Starbucks’ Earnings Beat Wall Street Forecasts Across The Board
Retail coffee chain Starbucks (SBUX) has reported fourth-quarter 2024 financial results that beat Wall Street forecasts on both the top and bottom lines. The Seattle-based roastery announced earnings per share (EPS) of $0.69 U.S., which topped the consensus expectation of $0.67 U.S. Revenue in the final quarter of last year came in at $9.40 billion U.S., which beat the $9.31 billion U.S. forecast on Wall Street. Sales were unchanged from a year earlier.The results come despite Starbucks reporting that its same-store sales declined for a fourth consecutive quarter. Management said that same-store sales fell 4%, fueled by a 6% decline in foot traffic at its coffee outlets. However, Wall Street was expecting a steeper drop of 5.5% in same-store sales.Within the U.S., same-store sales declined 4% as foot traffic to its cafes fell 8%. Outside of its home market, same-store sales at Starbucks’ international locations dropped 4%. In China, the company’s second-largest market, same-store sales slid 6%, fueled by a 4% dip in average ticket prices. The coffee giant has been relying on discounts in China to compete with domestic rivals such as Luckin Coffee.Under chief executive officer (CEO) Brian Niccol, Starbucks has undertaken a turnaround strategy that has involved everything from new executives to free coffee refills at its outlets.Starbucks’ stock has gained 7% in the last 12 months to trade at $100.39 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


